Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ANTIPSYCHOTIC OLANZAPINE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 44 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Raggi, MA; Casamenti, G; Mandrioli, R; Volterra, V
      A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure

      JOURNAL OF CHROMATOGRAPHY B
    2. Bernardo, M; Parellada, E; Lomena, F; Catafau, AM; Font, M; Gomez, JC; Lopez-Carrero, C; Gutierrez, F; Pavia, J; Salamero, M
      Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study

      PSYCHIATRY RESEARCH-NEUROIMAGING
    3. Rao, ML; Hiemke, C; Grasmader, K; Baumann, P
      Olanzapine: Pharmacology, pharmacokinetics and therapeutic drug monitoring

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    4. Esel, E; Basturk, M; Gonul, AS; Kula, M; Turan, MT; Yabanoglu, I; Sofuoglu, S
      Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients

      PSYCHONEUROENDOCRINOLOGY
    5. Kane, J
      Progress defined - short-term efficacy, long-term effectiveness

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    6. Weigmann, H; Gerek, S; Zeisig, A; Muller, M; Hartter, S; Hiemke, C
      Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: Evidence from a therapeutic drug monitoring service

      THERAPEUTIC DRUG MONITORING
    7. Hagg, S; Spigset, O; Lakso, HA; Dahlqvist, R
      Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    8. Bhana, N; Foster, RH; Olney, R; Plosker, GL
      Olanzapine - An updated review of its use in the management of schizophrenia

      DRUGS
    9. Tollefson, GD; Birkett, MA; Kiesler, GM; Wood, AJ
      Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

      BIOLOGICAL PSYCHIATRY
    10. Geyer, MA; Krebs-Thomson, K; Braff, DL; Swerdlow, NR
      Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

      PSYCHOPHARMACOLOGY
    11. van Waarde, A
      Measuring receptor occupancy with PET

      CURRENT PHARMACEUTICAL DESIGN
    12. Braus, DF; Schmitt, A; Czekalla, J; Severa, L
      Therapy-resistant psychotic-depressive disorder - Remission with a selective serotonin reuptake inhibitor in combination with olanzapine

      CLINICAL DRUG INVESTIGATION
    13. Lane, HY; Liu, HC; VandenBerg, CM; Su, MH; Jann, MW; Chang, WH
      Disposition of olanzapine in Chinese schizophrenic patients

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    14. Shadach, E; Gaisler, I; Schiller, D; Weiner, I
      The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin

      NEUROPSYCHOPHARMACOLOGY
    15. Carrillo, JA; Benitez, J
      Clinically significant pharmacokinetic interactions between dietary caffeine and medications

      CLINICAL PHARMACOKINETICS
    16. Riedel, M; Muller, N; Moller, HJ
      Atypical neuroleptics

      AKTUELLE NEUROLOGIE
    17. Chengappa, KNR; Pollock, BG; Parepally, H; Levine, J; Kirshner, MA; Brar, JS; Zoretich, RA
      Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    18. Grothe, DR; Calis, KA; Jacobsen, L; Kumra, S; DeVane, CL; Rapoport, JL; Bergstrom, RF; Kurtz, DL
      Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    19. Licht, RW; Olesen, OV; Friis, P; Laustsen, T
      Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    20. Meisenzahl, EM; Dresel, S; Frodl, T; Schmitt, GJE; Preuss, UW; Rossmuller, B; Tatsch, K; Mager, T; Hahn, K; Moller, HJ
      D-2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study

      JOURNAL OF PSYCHOPHARMACOLOGY
    21. Bigliani, V; Mulligan, RS; Acton, PD; Ohlsen, RI; Pike, VW; Ell, PJ; Gacinovic, S; Kerwin, RW; Pilowsky, LS
      Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [I-123]epidepride single photon emission tomography (SPET) study

      PSYCHOPHARMACOLOGY
    22. Coutureau, E; Gosselin, O; Di Scala, G
      Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats

      PSYCHOPHARMACOLOGY
    23. Schmitt, A; Braus, DF
      Effective treatment with olanzapine of a depressive syndrome with psychotic symptoms

      DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
    24. Lavalaye, J; Linszen, DH; Booij, J; Reneman, L; Gersons, BPR; van Royen, EA
      Dopamine D-2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia

      PSYCHIATRY RESEARCH-NEUROIMAGING
    25. Raedler, TJ; Knable, MB; Lafargue, T; Urbina, RA; Egan, MF; Pickar, D; Weinberger, DR
      In vivo determination of striatal dopamine D-2 receptor occupancy in patients treated with olanzapine

      PSYCHIATRY RESEARCH-NEUROIMAGING
    26. Geyer, MA; Krebs-Thomson, K; Varty, GB
      The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia

      NEUROPSYCHOPHARMACOLOGY
    27. Wrighton, SA; Ring, BJ
      Predicting drug interactions and pharmacokinetic variability with in vitromethods: The olanzapine experience

      DRUG METABOLISM REVIEWS
    28. Dresel, S; Mager, T; Rossmuller, B; Meisenzahl, E; Hahn, K; Moller, HJ; Tatsch, K
      In vivo effects of olanzapine on striatal dopamine D-2/D-3 receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study

      EUROPEAN JOURNAL OF NUCLEAR MEDICINE
    29. Callaghan, JT; Bergstrom, RF; Ptak, LR; Beasley, CM
      Olanzapine - Pharmacokinetic and pharmacodynamic profile

      CLINICAL PHARMACOKINETICS
    30. Bakshi, VP; Geyer, MA
      Alpha-1-adrenergic receptors mediate sensorimotor gating deficits producedby intracerebral dizocilpine administration in rats

      NEUROSCIENCE
    31. Markowitz, JS; DeVane, CL
      Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    32. Stephenson, CME; Pilowsky, LS
      Psychopharmacology of olanzapine - A review

      BRITISH JOURNAL OF PSYCHIATRY
    33. Moore, NA
      Olanzapine: preclinical pharmacology and recent findings

      BRITISH JOURNAL OF PSYCHIATRY
    34. Yamada, S; Harano, M; Annoh, N; Nakamura, K; Tanaka, M
      Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats

      BIOLOGICAL PSYCHIATRY
    35. Feifel, D; Priebe, K
      The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating

      PSYCHOPHARMACOLOGY
    36. Tauscher, J; Kufferle, B; Asenbaum, S; Fischer, P; Pezawas, L; Barnas, C; Tauscher-Wisniewski, S; Brucke, T; Kasper, S
      In vivo I-123 IBZM SPECT imaging of striatal dopamine-2 receptor occupancyin schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

      PSYCHOPHARMACOLOGY
    37. MACIAS WL; BERGSTROM RF; CERIMELE BJ; KASSAHUN K; TATUM DE; CALLAGHAN JT
      LACK OF EFFECT OF OLANZAPINE ON THE PHARMACOKINETICS OF A SINGLE AMINOPHYLLINE DOSE IN HEALTHY-MEN

      Pharmacotherapy
    38. LUCAS RA; GILFILLAN DJ; BERGSTROM RF
      A PHARMACOKINETIC INTERACTION BETWEEN CARBAMAZEPINE AND OLANZAPINE - OBSERVATIONS ON POSSIBLE MECHANISM

      European Journal of Clinical Pharmacology
    39. SEBENS JB; KOCH T; TERHORST GJ; KORF J
      OLANZAPINE-INDUCED FOS EXPRESSION IN THE RAT FOREBRAIN - CROSS-TOLERANCE WITH HALOPERIDOL AND CLOZAPINE

      European journal of pharmacology
    40. KAPUR S; ZIPURSKY RB; REMINGTON G; JONES C; DASILVA J; WILSON AA; HOULE S
      5-HT2 AND D-2 RECEPTOR OCCUPANCY OF OLANZAPINE IN SCHIZOPHRENIA - A PET INVESTIGATION

      The American journal of psychiatry
    41. CHAMBERS RA; CARACANSI A; WEISS G
      OLANZAPINE OVERDOSE CAUSE OF ACUTE EXTRAPYRAMIDAL SYMPTOMS

      The American journal of psychiatry
    42. TRAN PV; HAMILTON SH; KUNTZ AJ; POTVIN JH; ANDERSEN SW; BEASLEY C; TOLLEFSON GD
      DOUBLE-BLIND COMPARISON OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

      Journal of clinical psychopharmacology
    43. BAKSHI VP; GEYER MA
      PHENCYCLIDINE-INDUCED DEFICITS IN PREPULSE INHIBITION OF STARTLE ARE BLOCKED BY PRAZOSIN, AN ALPHA-1 NORADRENERGIC ANTAGONIST

      The Journal of pharmacology and experimental therapeutics
    44. TOLLEFSON GD; BEASLEY CM; TAMURA RN; TRAN PV; POTVIN JH
      BLIND, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT-EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL

      The American journal of psychiatry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/12/19 alle ore 15:07:42